CRISPR THERAPEUTICS AG Deferred State and Local Income Tax Expense (Benefit)
CRISPR THERAPEUTICS AG (CRSP) reported Deferred State and Local Income Tax Expense (Benefit) of -$18.00 thousand for the 12-month period ending 2025-12-31, per its 10-K filed 2026-02-12.
Financial Statements › Expense Statement › Income Tax
us-gaap:DeferredStateAndLocalIncomeTaxExpenseBenefit · last filed 2026-02-12
- CRISPR THERAPEUTICS AG deferred state and local income tax expense (benefit) for fiscal 2025 was -$18.00K, a 325.00% decline from fiscal 2024.
- CRISPR THERAPEUTICS AG deferred state and local income tax expense (benefit) for fiscal 2024 was $8.00K.
- CRISPR THERAPEUTICS AG deferred state and local income tax expense (benefit) for fiscal 2017 was -$297.00K.
- CRISPR THERAPEUTICS AG deferred state and local income tax expense (benefit) for fiscal 2016 was -$105.00K.
| Period end | Deferred State and Local Income Tax Expense (Benefit) 12 month |
|---|---|
| 2025-12-31 | -$18.00K 10-K · filed 2026-02-12 |
| 2024-12-31 | $8.00K 10-K · filed 2026-02-12 |
| 2017-12-31 | -$297.00K 10-K · filed 2020-02-12 |
| 2016-12-31 | -$105.00K 10-K · filed 2019-02-25 |
| 2015-12-31 | -$65.00K 10-K · filed 2018-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| IOVANCE BIOTHERAPEUTICS, INC. (IOVA) | United States | $4.897B | -6.51 |
| Scholar Rock Holding Corp (SRRK) | United States | $5.920B | -16.37 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |
| CG Oncology, Inc. (CGON) | United States | $6.095B | -27.95 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Denali Therapeutics Inc. (DNLI) | United States | $3.274B | -8.04 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B |